{
    "nct_id": "NCT04892173",
    "official_title": "A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC",
    "inclusion_criteria": "* Age greater than or equal to (>=) 60 years old\n* Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab\n* Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC\n* One primary tumor lesion amendable for intratumoral injection\n* Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following):\n\n  1. Estimated creatinine clearance >= 30 and less than (<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation), Grade >= 2 hearing loss or tinnitus, Grade >= 2 peripheral neuropathy, Eastern Cooperative Oncology Group (ECOG) Performance Status 2 or New York Heart Association Class 3\n  2. Age 70-74 years old with Geriatric 8 (G8) score less than or equal to (<=) 14\n  3. Age >= 75 years old\nHealthy volunteers allowed\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* Carcinoma of the nasopharynx, paranasal sinus(es), salivary gland, thyroid gland, or unknown primary\n* Non-squamous cell histology\n* Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC\n* Loco-regionally recurrent head & neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy\n* Prior or concurrent primary malignancy (including second synchronous head & neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent\n* Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization",
    "miscellaneous_criteria": ""
}